 |
|
Incomplete Financial Disclosure in a Study of Cell-Free Hemoglobin-Based Blood Substitutes and Risks of Myocardial Infarction and Death
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: I would like to report an incomplete financial disclosure resulting from my oversight in not including my involvement in a US Government Provisional Patent Application in the Financial Disclosures in the meta-analysis on cell-free hemoglobin-based blood substitutes (HBBSs) and risks of myocardial infarction and death.1
In the Financial Disclosures section of the article, I reported that I had been paid $10 000 by Hemosol Inc to review a cardiac surgery trial of its HBBS product and that I had served as an unpaid special government consultant to the Food and Drug Administration on the HBBS product Hemopure (made by Biopure Corp, Cambridge, Massachusetts). However, I failed to disclose that my name is listed with Dr Mark T. Gladwin and other National Institutes of Health investigators on a US Provisional Application relating to hemoglobin-based oxygen carriers (HBOCs) that was filed in August of 2007. The Provisional Application relates to . . . [Full Text of this Article]
Charles Natanson, MD
cnatanson@cc.nih.gov
Critical Care Medicine Department
Clinical Center
National Institutes of Health
Bethesda, Maryland
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Cell-Free Hemoglobin-Based Blood Substitutes and Risk of Myocardial Infarction and Death: A Meta-analysis
Charles Natanson, Steven J. Kern, Peter Lurie, Steven M. Banks, and Sidney M. Wolfe
JAMA. 2008;299(19):2304-2312.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Resolving Unreported Conflicts of Interest
DeAngelis and Fontanarosa
JAMA 2009;302:198-199.
FULL TEXT
|
